Home
Who we are
What we offer
Clients
Technologies
News
Contact
More
Follow Virtuvax on LinkedIn, Twitter or via www.virtuvax.nl .
Virtuvax for collaboration on your innovation in vaccine development or your biosimilar
Virtuvax' innovation in vaccine industry “vaccine development skating on start-ups”
Mucosis Announces Re-issue of Major Patent by US Patent Office USPTO
SynGEM publication paper of the month on ReSViNET
First-in-Human Results of SynGEM Demonstrate that the RSV Vaccine Is Well-Tolerated and Capable of I
New comment by UMC Utrecht on the SynGEM vaccine trial is a plea to consider the vaccine in an RSV c
Phase I clinical trial data of Mucosis intranasal vaccine against respiratory syncytial virus (RSV)
Virtuvax to attend DCVMN in Kunming
Matchmaking and contributing to a vaccine based Global insurance against Emerging Infections?
Meet Virtuvax @ BioWin Day 2016
